AI & TechnologyOctober 9, 2026·8 min read··Last updated: 2026-10-28

Iambic Therapeutics IPO Status: Priced at $16 for $150M, Now Trading on Nasdaq as IAM

The AI-drug-discovery startup priced a Nasdaq listing roughly 50% larger than its original ask, with ARK and Duquesne as non-binding anchors.

Trace Cohen
Founder & Editor-in-chief, Value Add VC — Angel investor, VC, family office, operator and founder · Co-founder of BrandYourself and Launch.it · 75 investments
75Investments3xFounder$200M+Funds Tracked

Quick Answer

As of October 28, 2026: Iambic Therapeutics is public and trades on the Nasdaq Global Select Market as IAM. It closed at $14.78 on October 28 (4:00 PM ET), a $700.6 million market cap per Yahoo Finance, 7.6% below its $16.00 IPO price (our arithmetic). The IPO priced on October 14, 2026, selling 9,375,000 shares for $150 million in gross proceeds, per the company and its final prospectus (424B4); insider lockups run 180 days.

As of October 28, 2026, Iambic Therapeutics trades on the Nasdaq Global Select Market as IAM and closed at $14.78, a $700.6 million market cap per Yahoo Finance, below its IPO price. It priced that IPO at $16.00 a share on October 14, selling 9,375,000 shares for $150 million, which implied about $758 million on its post-offering share count, according to the company's pricing announcement and final prospectus. IAM began trading October 15, closed as high as $23.81 on October 16, and has closed below its $16 IPO price every session since October 21, per Yahoo Finance.

Iambic IPO: Key Numbers (as of October 28, 2026)

DateEventAmount / Valuation / RevenueSource
Sep 21, 2026Files for a US IPO; deal originally reported at about $100M~$100M (reported target)Reuters via The Star
Oct 8, 2026Amended S-1 sets terms: 9.375M shares at $15-$17~$150M (midpoint)SEC EDGAR
Oct 14, 2026Prices IPO at $16.00; 9,375,000 shares; 30-day option for 1,406,250 more$150M grossCompany release; SEC 424B4
Oct 14, 2026Implied value at $16 on 47,400,796 shares outstanding after the offering~$758M (implied)SEC 424B4
Oct 15, 2026IAM debuts on Nasdaq; opens $16.15, closes $18.91 (+18.2%)$18.91 closeYahoo Finance
Oct 16, 2026Highest close so far (+48.8% vs IPO)$23.81 closeYahoo Finance
Oct 16, 2026Restated charter filed in connection with IPO completion (Form 8-K)ClosedSEC 8-K
Oct 27, 2026Lowest close so far$14.00 closeYahoo Finance
Oct 28, 2026Closing price (4:00 PM ET) and market cap, per Yahoo Finance$14.78 / $700.6MYahoo Finance
Oct 28, 2026EDGAR check: latest filings are the 424B4 (Oct 15), 8-K (Oct 16) and Form 4s (Oct 19); no 10-Q yetNo 10-Q filedSEC EDGAR
~Apr 12, 2027Insider lockup ends: 180 days after the Oct 14, 2026 prospectus (our arithmetic)180 daysSEC 424B4

The implied value is Value Add VC arithmetic on the prospectus share count, not a company figure. The lockup end date is our arithmetic from the prospectus date; underwriters can release shares early. We found no announcement of the underwriters exercising their option as of October 28, 2026. ARK and Duquesne's up-to-$60 million indication of interest was non-binding.

Iambic Therapeutics IPO. Gross proceeds: $150M (as of October 2026). Value Add VC card by Trace Cohen
$150M
9.375M shares
Gross proceeds
$16.00
range was $15-$17
IPO price
~$758M
Implied value at IPO
$77.3M
2025 net loss

Source: SEC EDGAR final prospectus (424B4), dated October 14, 2026.

Iambic Therapeutics IPO: From Terms to Pricing

Iambic Therapeutics filed an amended S-1 on October 8, 2026 setting terms for its Nasdaq IPO: 9.375 million shares priced at $15.00 to $17.00 apiece, with underwriters holding a 30-day option to buy up to 1.406 million additional shares. At the midpoint, that implies a $150 million raise and a roughly $758 million market cap.

J.P. Morgan, Jefferies, BofA Securities, and Citigroup are joint book-runners on the deal, which listed on the Nasdaq Global Select Market under the ticker IAM. It priced on October 14 at $16.00, inside that range, and began trading on Nasdaq under IAM on October 15.

Iambic's IPO Target Grew ~50% Between Filings

Iambic's deal size grew from an originally reported $100M target in September to $150M in its amended October terms

Dealroom/Pulse coverage of Iambic's September 21, 2026 filing; SEC EDGAR amended S-1, October 8, 2026

Data
Iambic's IPO Target Grew ~50% Between Filings
ItemValue
Original filing (Sept 21)~$100M target
Priced deal (Oct 14)$150M at $16
Est. net proceeds~$135M
Iambic's IPO Target Grew ~50% Between Filings: Iambic's deal size grew from an originally reported $100M target in September to $150M in its amended October terms

Who's Anchoring the Deal

ARK Investment Management and Duquesne Family Office have both indicated non-binding interest in buying up to $60 million of shares combined at the IPO price — a notable anchor commitment for a biotech that is still well short of profitability. Those indications weren't binding orders, but they gave the deal a visible demand floor before the roadshow.

Iambic reported a $77.3 million net loss in 2025 against just $9.4 million in collaboration revenue, underscoring how heavily the company has leaned on pharma partnerships — including ties to Nvidia and Qatar-linked backers noted in its original September filing — rather than product revenue to fund its pipeline. The company plans to use the roughly $135 million in expected net proceeds (about $155.9 million if underwriters exercise their option in full) to advance its lead candidate and earlier-stage programs.

What Iambic Is Actually Building

Iambic was founded in 2019 as Entos and is based in San Diego, California. It has raised roughly $461.8 million since founding from backers including Nvidia, Qatar's sovereign wealth fund (QIA), Catalio, Nexus Ventures, and Coatue Management, and holds pharma partnerships with Takeda, Lundbeck, Revolution Medicines, Jazz Pharmaceuticals, Bayer, and — announced the same day as its original September filing — AbbVie, according to Reuters' reporting on the September 21, 2026 filing, carried by The Star.

Iambic's lead candidate, IAM1363, is an oral HER2 inhibitor currently in an ongoing Phase 1/1b basket trial for patients with HER2-altered solid tumors, with a registrational trial that could start as early as 2027. Two earlier-stage candidates sit behind it: IAM217, a KIF18A allosteric inhibitor whose IND was submitted to the FDA on September 30, 2026, and IAM-C1, a CDK2/4 dual inhibitor with an IND expected in Q4 2026 — both pending regulatory clearance before Phase 1/2 trials can begin.

Iambic markets itself as an AI-native drug-discovery company, positioning its computational platform against both traditional biotech R&D and a growing cluster of AI-first drug companies that have raised large private rounds over the past two years. The table below compares Iambic's IPO terms to recent peers in that category.

CompanyFocusValuationDateStatus
ADARx PharmaceuticalsRNA therapeutics$1.81BSept 2026Priced IPO (ADRX)
Chai DiscoveryAI drug design platform$3.8B2026Private, Series C
Iambic TherapeuticsAI-native small-molecule drug discovery~$758MOct 2026Priced IPO (IAM) at $16

Sources: SEC EDGAR, and our own reporting on ADARx and Chai Discovery, checked October 21, 2026.

What the headline misses

The deal priced, but early trading shows how fragile the number is. IAM closed 48.8% above its $16 IPO price on its second day, then gave all of that back within four sessions and kept falling, closing at $14.78 on October 28, about 7.6% below the IPO price (our arithmetic), per Yahoo Finance. The roughly $758 million value is our arithmetic on prospectus share counts, and ARK and Duquesne's combined $60 million of indicated interest was explicitly non-binding; the final prospectus does not say how much they bought.

The business itself carries real pre-revenue risk. A $77.3 million net loss against $9.4 million in collaboration revenue means Iambic is years away from its own product revenue, and its lead candidate IAM1363 is still in an early basket trial — a registrational trial isn't expected to start before 2027 at the soonest. Investors here are pricing a drug-discovery pipeline, not an approved therapy.

Context also matters for the deal's reception: this quarter's broader biotech IPO pipeline has produced far more S-1 filings than actual pricings, meaning Iambic is debuting into a market that has been more willing to file than to buy. Iambic priced in the upper half of its range rather than above it, and the stock's slide below the IPO price within a week is the market's first verdict on AI-native biotech appetite. A day later, City Therapeutics set its own terms for a $175 million IPO, giving investors a same-week comp from a different bank syndicate and a different RNAi-based modality.

Is the Deal Size Increase a Good Sign?

Going from a placeholder ~$100 million target in September to a $150 million deal priced at $16 in October, with two large institutional names attached as non-binding anchors, was a meaningfully stronger outcome than Iambic looked set for three weeks earlier. That's real progress, not just paperwork — amended S-1s with firm price ranges and named anchor investors typically come after banks have already tested demand with institutional investors.

Whether that translates into a durable public-market valuation is a separate question that IAM's first two weeks of trading, which ended below the IPO price, have only started to answer. A $758 million implied cap on a company with a single Phase 1/1b asset and no near-term path to revenue is a bet on Iambic's AI-discovery platform generalizing to a broader pipeline — the same bet every AI-native biotech is asking public investors to make, just with less dilution risk than Iambic's earlier private backers took on.

The bottom line:

Iambic Therapeutics raised $150M at $16 a share, about a $758M implied value and ~50% more than its original ask — but IAM was back below its IPO price within a week, and the $77.3M net loss behind it is a reminder this is a pre-revenue drug-discovery bet.

Track the original filing in our Pulse coverage of Iambic's amended terms, see how other AI drug-discovery startups are raising in our look at the category, and read more analysis at Value Add VC.

Get VC data most people never see

— free to subscribe

Trace's notes on venture, AI and startups, a few times a week. Join 5,000+ subscribers. No spam.

No spam, unsubscribe anytime. Sent via Substack · Privacy · or subscribe on Substack ↗

Add Value Add VC as a preferred source on Google

Frequently Asked Questions

Did the Iambic IPO happen, and where does Iambic trade?

Yes. As of October 28, 2026, Iambic Therapeutics is public. It priced its IPO at $16.00 a share on October 14, 2026 and began trading on the Nasdaq Global Select Market under the ticker IAM on October 15, per the company's pricing announcement. Its October 16, 2026 Form 8-K says Iambic filed its restated charter that day in connection with the completion of the IPO.

What is Iambic's market cap?

As of October 28, 2026, Yahoo Finance listed Iambic's market cap at $700.584 million, with IAM closing at $14.78. At the $16.00 IPO price, the 47,400,796 shares the final prospectus says were outstanding after the offering imply about $758 million (our arithmetic).

How much did Iambic Therapeutics raise in its IPO?

Iambic sold 9,375,000 shares at $16.00 for $150 million in gross proceeds, with underwriters holding a 30-day option to buy up to 1,406,250 more shares, per its October 14, 2026 pricing announcement. The final prospectus estimates net proceeds of about $135.0 million, or about $155.9 million if the option is exercised in full. As of October 28, 2026, we found no announcement that the option had been exercised.

How has Iambic stock traded since the IPO?

As of October 28, 2026, IAM closed at $14.78, below its $16.00 IPO price, per Yahoo Finance. It opened at $16.15 on October 15, had its highest close of $23.81 on October 16, and its lowest close of $14.00 on October 27.

When does the Iambic IPO lockup expire?

Directors, officers and substantially all holders agreed not to sell for 180 days following the date of the final prospectus, which is dated October 14, 2026, per the 424B4. That puts the end of the lockup around April 12, 2027 (our arithmetic). The underwriters can release shares early at their discretion.

Who are the underwriters and anchor investors in Iambic's IPO?

J.P. Morgan, Jefferies, BofA Securities, and Citigroup were joint book-runners on the deal. ARK Investment Management and Duquesne Family Office indicated non-binding interest in buying up to $60 million of shares combined at the IPO price, per the final prospectus.

What does Iambic Therapeutics do?

Iambic is an AI-drug-discovery company whose lead candidate, IAM1363, is an oral HER2 inhibitor in an ongoing Phase 1/1b basket trial for HER2-altered solid tumors. Two earlier-stage candidates, IAM217 and IAM-C1, are moving toward Phase 1/2 trials pending FDA clearance.

Is Iambic Therapeutics profitable?

No. Iambic reported a $77.3 million net loss in 2025 against $9.4 million in collaboration revenue, per its final prospectus. As of October 28, 2026, it had not yet filed its first quarterly report (10-Q) as a public company on SEC EDGAR.

Explore 45+ free VC tools, dashboards, and recommended startup software.